MyStart Health LLC: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.mystarthealth.com in August 2025 and has observed that your website offers compounded semaglutide. As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “The following claims concerning your compounded semaglutide products appear on your website:”

2. 2

   “• “Generic Ozempic” • “Save with generics that offer the same active ingredients and results.””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

www.mystarthealth.com returned a live site on 2026-08-09 titled "MyStart Weight Loss Program", running a stacked promotion ("$150 Off + Lifetime 25% Off"), advertising "No Membership fees!" and a five-minute qualification flow with a working sign-up — an operating seller. Neither cited phrase appears: a sweep of the site for this project on the same date returned zero occurrences of "generic" across its marketing, legal and funnel pages in both languages.

"Save with generics that offer the same active ingredients and results" is the sentence this whole roster is really about, because it states the bargain the reader is being offered. Two things in it do not survive contact with the facts. There is no generic Ozempic — a generic is an FDA-approved copy of an approved drug, and no generic semaglutide has been approved, so the category the sentence invokes does not exist. And "results" is a step beyond "ingredients": the outcomes people associate with these drugs come from trials run on a specific approved product at a specific titrated dose, and a compounded preparation has not been studied that way, whatever it contains. What is genuinely true is the money — compounded semaglutide is usually much cheaper, and that is a real reason people buy it. The letter does not dispute that and makes no finding about the product's contents, sterility or potency. It disputes the explanation attached to the price. That distinction is worth keeping, because a seller who explains a low price by claiming approved-product equivalence has told you nothing about why it is low, and the real answers — a different dose form, a different supply chain, no approved application behind it — are the ones that determine what you are actually receiving. Neither cited phrase appears on the site today.

See our full review of MyStart Health LLC for pricing, states served, and what’s included.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence MyStart Health LLC failed to respond.